By Fineline Cube Akeso Biopharma (HKG: 9926) announced a partnership with Jumpcan Pharmaceutical (SHA: 600566) granting Jumpcan exclusive promotion rights to Yixining (ebronucimab) in mainland China. Jumpcan will pay Akeso a RMB 80 million licensing fee and up to RMB 10 million in milestone payments, taking responsibility for commercialization, promotion, and sales.
Partnership Structure & Drug Profile
| Item | Detail |
|---|---|
| Licensor | Akeso Biopharma (9926.HK) |
| Licensee | Jumpcan Pharmaceutical (600566.SH) |
| Asset | Yixining (ebronucimab) |
| Rights | Exclusive promotion rights in mainland China |
| Financial Terms | RMB 80 M licensing fee + up to RMB 10 M milestone |
| Mechanism | PCSK9 inhibitor (blocks PCSK9-LDLR binding, increases LDLR surface expression) |
| Approval | China approval Sept 2024; included in NRDL |
| Indication | Primary hypercholesterolemia and mixed dyslipidemia |
Market Impact & Commercial Outlook
- China PCSK9 Market: Valued at ¥3 billion (~US$420 million) in 2025, growing at 25% CAGR driven by cardiovascular disease burden
- NRDL Advantage: Inclusion in National Reimbursement Drug List ensures broad patient access and rapid hospital adoption
- Competitive Landscape: Competes with Repatha (Amgen) and Leqvio (Novartis); Yixining’s local manufacturing and promotion network offer cost advantages
- Revenue Potential: Analysts project ¥800 million–1.2 billion (US$110–170 million) peak annual sales in China by 2028, assuming 15% PCSK9 market share
- Strategic Value: Akeso monetizes approved asset while focusing on R&D; Jumpcan gains entry into high‑growth cardiovascular segment with de‑risked product
- Next Steps: Jumpcan to initiate promotion activities Q2 2026; sales force training and hospital listing to begin immediately
Forward‑Looking Statements
This brief contains forward‑looking statements regarding commercial launch timelines, market penetration, and revenue projections for Yixining. Actual results may differ due to competitive dynamics, hospital adoption rates, and reimbursement policy changes.-Fineline Info & Tech